Pyrazolam
 | |
| Systematic (IUPAC) name | |
|---|---|
| 8-Bromo-1-methyl-6-(pyridin-2-yl)-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine | |
| Clinical data | |
| |
| Oral, Sublingual, rectal | |
| Pharmacokinetic data | |
| Half-life | 17 hours |
| Identifiers | |
| 39243-02-2 | |
| PubChem | CID 12562545 |
| ChemSpider | 15417688 |
| Chemical data | |
| Formula | C16H12BrN5 |
| 354.204 g/mol | |
|
SMILES
| |
| |
Pyrazolam is a benzodiazepine derivative originally developed by a team led by Leo Sternbach at Hoffman-La Roche in the 1970s,[1] and subsequently "rediscovered" and sold as a designer drug and research chemical starting in 2012.[2]
Pyrazolam has structural similarities to alprazolam[3] and bromazepam. Unlike other benzodiazepines pyrazolam does not appear to undergo metabolism, instead being excreted unchanged in the urine.[2][4] It is most selective for the α2 and α3 receptor subtypes.[5]
References
- ↑ US 3954728, "Preparation of triazolo benzodiazepines and novel compounds"
- ↑ 2.0 2.1 Moosmann, B.; Hutter, M.; Huppertz, L. M.; Ferlaino, S.; Redlingshöfer, L.; Auwärter, V. (2013). "Characterization of the designer benzodiazepine pyrazolam and its detectability in human serum and urine". Forensic Toxicology 31 (2): 263. doi:10.1007/s11419-013-0187-4.
- ↑ Hester Jr, J. B.; Rudzik, A. D.; Kamdar, B. V. (1971). "6-Phenyl-4H-s-triazolo[4,3-a][l,4]benzodiazepines Which Have Central Nervous System Depressant Activity". J. Med. Chem 14 (11): 1078–1081. PMID 5165540.
- ↑ Characterization of the designer benzodiazepines pyrazolam and flubromazepam and study on their detectability in human serum and urine samples, B. Moosmann, M. Hutter, L. M. Huppertz and V. Auwärter
- ↑ Hester, J. B.; von Voigtlander, P. (1979). "6-Aryl-4H-s-triazolo[4,3-a][1,4]benzodiazepines. Influence of 1-substitution on pharmacological activity". Journal of Medicinal Chemistry 22 (11): 1390. doi:10.1021/jm00197a021.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||